Teva Branded Pharmaceutical Products R&D
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Teva Branded Pharmaceutical Products R&D sits in the top decile of US sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count).
Teva Branded Pharmaceutical Products R&D: 167 sponsored US clinical trials, 6 recruiting.
Teva Branded Pharmaceutical Products R&D sponsors 167 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 131 completed. 89 of these trials are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Asthma, with 13 trials.
Top-decile sponsor footprint
Teva Branded Pharmaceutical Products R&D ranks in the top decile of sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
131 of 159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
167 total, page 3 of 4
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
NCT01424813
A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
NCT01758978
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
NCT01723228
Safety Study of Albuterol Spiromax® in Subjects With Asthma
NCT01698320
Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)
NCT01697956
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
NCT01632540
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
NCT01624480
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
NCT01576718
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01578785
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
NCT01508936
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
NCT01479621
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT01348919
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
NCT01290887
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
NCT01311713
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
NCT01287039
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
NCT01307319
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
NCT01285323
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
NCT01302587
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
NCT01270464
A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives
NCT01291004
Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
NCT01240863
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
NCT01085084
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
NCT01223365
A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing
NCT01218009
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
NCT01085097
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
NCT01088984
A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
NCT01178125
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
NCT01067521
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
NCT01133626
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
NCT01047319
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
NCT01134705
A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma
NCT01058863
A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)
NCT01056159
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
NCT01024608
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
NCT00977665
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
NCT00988052
Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
NCT00988247
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
NCT00964730
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
NCT00936676
A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel
NCT00868361
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
NCT00877006
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
NCT00854360
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
NCT00724048
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
NCT00696332
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
NCT00605215
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
NCT00509145
A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021
NCT00544882
Albuterol HFA MDI in Pediatric Participants With Asthma
NCT00577655
Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
NCT00530062
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
NCT00462943
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 37 |
| Phase 3 | 79 |
| Phase 4 | 10 |
Therapeutic Areas
What is open in the Teva Branded Pharmaceutical Products R&D pipeline
6 recruiting of 167 indexed (4% open); 131 completed (78%).
Phase mix: 89 late (III/IV) vs 74 early (I/II) (balanced across stages).
Top condition: Asthma (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Teva Branded Pharmaceutical Products R&D: open-pipeline peers nationwide
Peers matched on 167 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Teva Branded Pharmaceutical Products R&D sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 167 trials (± recruiting share)
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Bayer · 4% recruiting · 591 trials
Related
What to do with this Teva Branded Pharmaceutical Products R&D page
167 registered trials is a research-attention snapshot, not an endorsement of Teva Branded Pharmaceutical Products R&D or any single study.
- 6 of Teva Branded Pharmaceutical Products R&D's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Asthma is the condition Teva Branded Pharmaceutical Products R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Teva Branded Pharmaceutical Products R&D pipeline card: 167 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.